By Pete Najarian, co-founder of OptionMonsterNEW YORK ( OptionMonster) -- Nektar Therapeutics (NKTR - Get Report) has some potentially high-value drugs in its pipeline, and bullish option traders are stepping in.
Nektar Bulls Fight Through Pain
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.